Despite launching years after the next-generation sequencing systems from Illumina and Thermo Fisher, officials at the German molecular biology company Qiagen see an opening for their GeneReader NGS offering.

“Labs struggle with NGS adoption, whether it’s with fragmented workflows or the technical challenges,” says Jonathan Arnold, senior director of marketing at Qiagen, whose North American headquarters are in Germantown, Md. “We’re not launching a sequencer or a box, but launching a complete solution in itself.”

The lead item in  the December “Put It on the Board” section  of CAP TODAY.  Read the whole shebang.